Company intelligence / Profile preview

Osteologix

Ownership: Private
Development stage: Other

Overview

Lead product candidate NB S101 (strontium malonate) completed a positive Phase II trial in postmenopausal women with low bone mineral density. The study met its primary endpoint by significantly reducing CTX‑1, a biomarker of bone resorption. NB S101 showed greater or equivalent efficacy compared to Protelos® (strontium ranelate), an approved osteoporosis drug in Europe. The company subsequently licensed global rights outside the US for this compound to Servier Research Group. No further clinical results reported since then.

Therapeutic areas: OtherEndocrinologyRheumatology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

strontium malonate

Partnerships

Exclusive global license agreement with Servier Research Group for development and commercialization of NB S101/strontium salts outside the United States.

Beyond the preview

Go deeper on Osteologix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osteologix.